With over 20 years of experience, CPC Scientific is a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO) that specialize in synthetic GMP peptides, oligonucleotides, and peptide-oligonucleotide conjugates (POCs), while offering a full range of research-grade custom and catalog products. Our integrated service model is designed to support partners through the most critical phases of drug development, with a particular focus on late-phase development, large-scale manufacturing, and commercial production. From initial discovery (mg quantities) to full commercialization (100 kgs), we provide the expertise and robust infrastructure to accelerate your peptide and oligonucleotide programs to success.
CPC Scientific meticulously follows FDA and ICH guidelines for CGMP manufacturing, and we provide complete support for your IND and NDA filings in the USA and all international filings and required regulatory support for your active pharmaceutical ingredients (APIs). Our New Chemical Entity (NCE) development program involves process development, process validation, analytical method development, method validation, stability studies, regulatory support, and assistance preparing regulatory documents. We also have the flexibility, pre-qualified workspace, and robust supply chain to incorporate new projects into our pipeline rapidly. We understand that delivery time is critical to your project’s success, and we have the capacity and flexibility to accept new projects and initiate production sooner than many leading CDMOs.
In June 2025, CPC Scientific’s parent company, Medtide Inc., was officially listed on the main board of the Hong Kong Stock Exchange, marking a major milestone that reflects our continued growth and global impact.